Results
1 -
10 of
28CM-Dextran-Polyalcohol-Camptothecin Conjugate, Polymer Drugs in the Clinical Stage A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan, Cancer Chemotherapy and Pharmacology A possible mechanism for the long-lasting antitumor effect of the macromolecular conjugate DE-310: mediation by cellular uptake and drug release of its active camptothecin analog DX-8951, Cancer Chemotherapy and Pharmacology A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5??days every 3??weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan, Cancer Chemotherapy and Pharmacology Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice, Cancer Chemotherapy and Pharmacology Multimodale palliative Behandlung des Pankreaskarzinoms, Der Onkologe A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer, Investigational New Drugs A Phase II Study of Intravenous Exatecan Mesylate (DX-8951f) Administered Daily for Five Days Every Three Weeks to Patients with Metastatic Adenocarcinoma of the Colon or Rectum, Investigational New Drugs Pancreatic cancer: An update, Current Oncology Reports Chemotherapy for advanced pancreatic cancer: Past, present, and future, Current Oncology Reports